Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $55.00 at Stifel Nicolaus

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target upped by Stifel Nicolaus from $50.00 to $55.00 in a research note published on Friday,Benzinga reports. They currently have a hold rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently weighed in on the stock. TD Cowen increased their price target on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Cantor Fitzgerald increased their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 30th. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $40.00 to $65.00 in a research note on Thursday, October 9th. Finally, Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Stock Up 4.5%

NASDAQ SUPN opened at $51.48 on Friday. Supernus Pharmaceuticals has a 52 week low of $29.16 and a 52 week high of $57.65. The business’s fifty day simple moving average is $48.27 and its 200-day simple moving average is $42.37. The firm has a market cap of $2.95 billion, a PE ratio of -151.41, a P/E/G ratio of 0.60 and a beta of 0.71.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. During the same period in the prior year, the company posted $0.69 EPS. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. Research analysts expect that Supernus Pharmaceuticals will post 2.38 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 59,900 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the completion of the transaction, the chief executive officer directly owned 1,206,578 shares in the company, valued at $61,016,649.46. This trade represents a 4.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the transaction, the vice president directly owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 116,945 shares of company stock worth $5,726,000 over the last 90 days. 8.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. Invesco Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 4.4% in the first quarter. Invesco Ltd. now owns 530,631 shares of the specialty pharmaceutical company’s stock valued at $17,378,000 after purchasing an additional 22,562 shares in the last quarter. Nuveen LLC purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at approximately $4,393,000. Quantbot Technologies LP acquired a new position in shares of Supernus Pharmaceuticals in the first quarter worth $103,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter worth $46,000. Finally, Martingale Asset Management L P raised its stake in shares of Supernus Pharmaceuticals by 28.3% in the first quarter. Martingale Asset Management L P now owns 57,199 shares of the specialty pharmaceutical company’s stock valued at $1,873,000 after acquiring an additional 12,607 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.